FDA Puts Partial Hold On Aeglea's Rare Disorder Trial In Pediatric Patients

• Aeglea BioTherapeutics Inc (NASDAQ: AGLE) received an FDA letter responding to a recently submitted protocol amendment for the Phase 1/2 trial of pegtarviliase for Classical Homocystinuria.

• Classical Homocystinuria is a rare disorder of methionine metabolism, leading to an abnormal accumulation of homocysteine and its metabolites in blood and urine.

• The protocol amendment requested the inclusion of adolescent patients at clinical trial sites in the U.S.

• The FDA stated that the protocol did not provide adequate justification and evidence to support the prospect of direct clinical benefit for pediatric patients.

• Also Read: Aeglea Bio Feels FDA Refusal Pinch, Cuts Workforce, Shifts Pipeline Focus

• The agency placed the trial on partial clinical hold for enrolling patients under 18 years of age under this Investigational New Drug (IND).

• The company believes the letter will not impact the planned enrollment and dosing of patients aged 18 & above.

• Enrollment in the trial remains on track, and Aeglea continues to expect to announce data in the fourth quarter of 2022, including data from cohort 3.

• Price Action: AGLE shares are down 3.64% at $0.53 on the last check Tuesday.

See more from Benzinga

• Pfizer Touts Positive Data From Prostate Cancer Combo Therapy Trial

• Autolus Therapeutics Stock Jumps After Bristol Myers Pact For Safety Switch System

• Trump's Former Secretary Of State Tillerson Says Unaware That Indicted Ally Was Privy To 'Sensitive' Disc

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.